Curis, Inc. announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Development.

Dr. Geissler joins Curis with over two decades of progressive experience developing and directing strategic operations and health care management initiatives; he is a board-certified surgeon and immunologist with a background in global medical affairs and clinical research. He joins Curis from Horizon Therapeutics serving as Vice President, Medical Affairs, where he led and directed the development and execution of the Medical Affairs strategy and operations for their comprehensive marketed product portfolio and investigational products across rare and ultra-rare disease indications. Dr. Steinmann joins Curis with over twenty years of clinical experience; she is a board-certified pediatric hematologist/oncologist and pediatric emergency medicine physician with a background in global clinical development and clinical research.

Previously, she worked at Takeda, where she served as consultant, to their oncology development program. Before Takeda, she worked at Grifols, as an Executive Medical Director for Orphan Diseases. Ms. Ferrari is an end-to-end drug development professional with twenty years of biotech industry experience.

Previously, she led program management and clinical operations at Aileron Therapeutics as Vice President, Clinical Development and Program Management. Earlier, Ms. Ferrari had a lengthy tenure at ArQule, working in positions of increasing responsibilities within clinical operations and clinical development in both oncology and rare disease.